Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides

This study has been terminated.

Study NCT00400101 Information provided by Swiss Tropical & Public Health Institute

First Received: November 15, 2006 No Changes Posted

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been terminated.
Estimated Study Completion Date:	October 2005
Estimated Primary Completion Date:	No date given

No publications provided by Swiss Tropical & Public Health Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Okitsu SL, Silvie O, Westerfeld N, Curcic M, Kammer AR, Mueller MS, Sauerwein RW, Robinson JA, Genton B, Mazier D, Zurbriggen R, Pluschke G. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS ONE. 2007 Dec 5;2(12):e1278.

Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, Schroller S, Vounatsou P, Mueller MM, Tanner M, Zurbriggen R. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS ONE. 2007 Oct 10;2(10):e1018.